SCHEMBL4098633

SCHEMBL4098633

C[S+]([O-])c1nc(-c2ccc(Cl)cc2Cl)c2[nH]cnc2n1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 2/20 0.50
ADORA3 P0DMS8 5/20 0.41
ADORA1 P30542 3/20 0.39
ADORA2A P29274 1/20 0.38
JAK2 O60674 2/20 0.36
PIK3CA P42336 2/20 0.35
CRHR1 P34998 2/20 0.35
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
PDPK1 O15530 2/20 0.34
CDK2 P24941 1/20 0.34
FLT3 P36888 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ADORA2B P29275 1/20 0.33
BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13765775 0.81 DPP4 (0.40) HSP90AB1CRHR1DPP4DPP8
SCHEMBL4095820 0.76 HSP90AB1 (0.50) HSP90AB1ADORA3ADORA1ADORA2AJAK2
SCHEMBL3914323 0.68 PDPK1 (0.56) DPP4PDPK1CDK2
SCHEMBL15444885 0.67 HSD11B1 (0.46) HSP90AB1CRHR1DPP4DPP8KDM4E
SCHEMBL4080406 0.65 DPP4 (0.46) HSP90AB1DPP4DPP8HPGDBRAF
SCHEMBL4089680 0.62 DPP4 (0.46) HSP90AB1PIK3CACRHR1DPP4DPP8
SCHEMBL4097131 0.60 CRHR1 (0.43) HSP90AB1PIK3CACRHR1DPP4DPP8
SCHEMBL4094400 0.60 HSP90AB1 (0.55) HSP90AB1CRHR1DPP4DPP8KDM4E
SCHEMBL5089390 0.59 DPP4 (0.38) CRHR1DPP4DPP8KDM4EHPGD
SCHEMBL3367392 0.59 NOS1 (0.42) HSP90AB1PIK3CACRHR1DPP4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
EP-2004648-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER Vernalis (R&D) Limited (GB) 2008-12-24 EP disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P HSP90AB1 2/4885ADORA3 1010/4885ADORA1 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.